JP2022509262A5 - - Google Patents
Info
- Publication number
- JP2022509262A5 JP2022509262A5 JP2021530913A JP2021530913A JP2022509262A5 JP 2022509262 A5 JP2022509262 A5 JP 2022509262A5 JP 2021530913 A JP2021530913 A JP 2021530913A JP 2021530913 A JP2021530913 A JP 2021530913A JP 2022509262 A5 JP2022509262 A5 JP 2022509262A5
- Authority
- JP
- Japan
- Prior art keywords
- patient
- pharmaceutical composition
- composition according
- breast cancer
- abemaciclib
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025050208A JP2025094216A (ja) | 2018-11-30 | 2025-03-25 | 乳癌を有する女性におけるアベマシクリブと組み合わせたエラセストラント |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862773960P | 2018-11-30 | 2018-11-30 | |
| US62/773,960 | 2018-11-30 | ||
| PCT/US2019/063239 WO2020112765A1 (en) | 2018-11-30 | 2019-11-26 | Elacestrant in combination with abemaciclib in women with breast cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025050208A Division JP2025094216A (ja) | 2018-11-30 | 2025-03-25 | 乳癌を有する女性におけるアベマシクリブと組み合わせたエラセストラント |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022509262A JP2022509262A (ja) | 2022-01-20 |
| JP2022509262A5 true JP2022509262A5 (https=) | 2022-12-02 |
Family
ID=68966023
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021530913A Pending JP2022509262A (ja) | 2018-11-30 | 2019-11-26 | 乳癌を有する女性におけるアベマシクリブと組み合わせたエラセストラント |
| JP2025050208A Pending JP2025094216A (ja) | 2018-11-30 | 2025-03-25 | 乳癌を有する女性におけるアベマシクリブと組み合わせたエラセストラント |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025050208A Pending JP2025094216A (ja) | 2018-11-30 | 2025-03-25 | 乳癌を有する女性におけるアベマシクリブと組み合わせたエラセストラント |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US20220117963A1 (https=) |
| EP (1) | EP3886826A1 (https=) |
| JP (2) | JP2022509262A (https=) |
| KR (1) | KR20210097170A (https=) |
| CN (1) | CN113164415A (https=) |
| AU (1) | AU2019388900B2 (https=) |
| BR (1) | BR112021010169A2 (https=) |
| CA (1) | CA3120368A1 (https=) |
| EA (1) | EA202191165A1 (https=) |
| IL (1) | IL283502A (https=) |
| JO (1) | JOP20210125A1 (https=) |
| MA (1) | MA54293A (https=) |
| MX (1) | MX2021005876A (https=) |
| MY (1) | MY209833A (https=) |
| PH (1) | PH12021551235A1 (https=) |
| SG (1) | SG11202105455RA (https=) |
| UA (1) | UA129403C2 (https=) |
| WO (1) | WO2020112765A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112021003440A2 (pt) | 2018-09-07 | 2021-05-18 | Sanofi | sais de 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil) pirrolidin-3-il]oxifenil]-8,9-di-hidro-7h-benzo[7]anuleno-2-carboxilato de metila e seu processo de preparação |
| EP4037768B1 (en) | 2019-10-01 | 2023-10-11 | Sanofi | Novel substituted 6,7-dihydro-5h-benzo[7]annulene compounds, processes for their preparation and therapeutic uses thereof |
| AU2020399168A1 (en) | 2019-12-09 | 2022-07-28 | Sanofi | Crystalline form of a 7H-benzo[7]annulene-2-carboxylic acid derivative |
| TW202146007A (zh) | 2020-02-27 | 2021-12-16 | 法商賽諾菲公司 | 包含阿培利司（ａｌｐｅｌｉｓｉｂ）與６－（２，４－二氯苯基）－５－［４－［（３ｓ）－１－（３－氟丙基）吡咯啶－３－基］氧苯基］－８，９－二氫－７ｈ－苯并［７］輪烯－２－羧酸之組合 |
| TW202233572A (zh) | 2020-10-19 | 2022-09-01 | 法商賽諾菲公司 | 新穎之經取代的6,7-二氫-5h-苯並[7]輪烯衍生物，其製備方法及其治療用途 |
| WO2022084280A1 (en) | 2020-10-19 | 2022-04-28 | Sanofi | Substituted 6,7-dihydro-5h-benzo[7]annulene compounds and their derivatives, processes for their preparation and therapeutic uses thereof |
| WO2022106711A1 (en) * | 2020-11-23 | 2022-05-27 | Sanofi | Combination comprising abemaciclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid |
| CN114146182A (zh) * | 2021-11-12 | 2022-03-08 | 深圳大学 | Cdk4/6抑制剂与铂类化疗药物在制备治疗肿瘤的药物中的用途 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20250152679A (ko) * | 2015-04-29 | 2025-10-23 | 래디어스 파마슈티컬스, 인코포레이티드 | 암을 치료하는 방법 |
| AU2017235450A1 (en) * | 2016-03-15 | 2018-08-16 | Merrimack Pharmaceuticals, Inc. | Methods for treating ER+, HER2-, HRG+ breast cancer using combination therapies comprising an anti-ErbB3 antibody |
| WO2018017410A1 (en) * | 2016-07-22 | 2018-01-25 | Eli Lilly And Company | Combination therapy of abemaciclib and a pi3 kinase/mtor dual inhibitor for use in the treatment of breast cancer |
-
2019
- 2019-11-26 MX MX2021005876A patent/MX2021005876A/es unknown
- 2019-11-26 KR KR1020217020321A patent/KR20210097170A/ko not_active Ceased
- 2019-11-26 EP EP19824087.1A patent/EP3886826A1/en active Pending
- 2019-11-26 MY MYPI2021002887A patent/MY209833A/en unknown
- 2019-11-26 MA MA054293A patent/MA54293A/fr unknown
- 2019-11-26 UA UAA202102817A patent/UA129403C2/uk unknown
- 2019-11-26 AU AU2019388900A patent/AU2019388900B2/en active Active
- 2019-11-26 EA EA202191165A patent/EA202191165A1/ru unknown
- 2019-11-26 US US17/298,198 patent/US20220117963A1/en not_active Abandoned
- 2019-11-26 WO PCT/US2019/063239 patent/WO2020112765A1/en not_active Ceased
- 2019-11-26 JO JOP/2021/0125A patent/JOP20210125A1/ar unknown
- 2019-11-26 SG SG11202105455RA patent/SG11202105455RA/en unknown
- 2019-11-26 CA CA3120368A patent/CA3120368A1/en active Pending
- 2019-11-26 BR BR112021010169-1A patent/BR112021010169A2/pt unknown
- 2019-11-26 JP JP2021530913A patent/JP2022509262A/ja active Pending
- 2019-11-26 CN CN201980079089.6A patent/CN113164415A/zh active Pending
-
2021
- 2021-05-27 IL IL283502A patent/IL283502A/en unknown
- 2021-05-28 PH PH12021551235A patent/PH12021551235A1/en unknown
-
2025
- 2025-03-25 JP JP2025050208A patent/JP2025094216A/ja active Pending
- 2025-05-02 US US19/197,091 patent/US20250268899A1/en active Pending
- 2025-09-24 US US19/338,117 patent/US20260014153A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022509262A5 (https=) | ||
| JP5543956B2 (ja) | 癌の処置のための方法および組成物 | |
| JP2020516646A5 (https=) | ||
| JPWO2020111018A5 (https=) | ||
| FI3463345T3 (fi) | Farmaseuttisia yhdistelmiä | |
| JP2019529581A5 (https=) | ||
| JP2017516802A5 (https=) | ||
| JP2025509510A5 (https=) | ||
| JP2019508476A5 (https=) | ||
| TW202120096A (zh) | 使用包含atp競爭性akt抑制劑、cdk4/6抑制劑及氟維司群之組合療法治療乳癌 | |
| JP2020504129A (ja) | 非アルコール性脂肪性肝炎（ｎａｓｈ）および肝線維症のための併用療法 | |
| MX2022006566A (es) | Tratamientos conjuntos para tratamiento de cancer de mama. | |
| MX2024010637A (es) | Nuevas combinaciones terapeuticas para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas. | |
| JP2017537927A5 (https=) | ||
| JP2016505050A5 (https=) | ||
| JP2019535830A5 (https=) | ||
| EP3654967A1 (en) | Use of eribulin and cyclin dependent kinase inhibitors in the treatment of cancer | |
| JP2024512558A5 (https=) | ||
| RU2019126627A (ru) | Схема введения доз комбинации церитиниба и молекулы антитела к pd-1 | |
| JP2018522881A5 (https=) | ||
| JP2022520859A5 (https=) | ||
| CN118178393A (zh) | 一种act001组合物的抗肿瘤用途 | |
| RU2021115204A (ru) | Элацестрант в комбинации с абемациклибом у женщин с раком молочной железы | |
| JP2025521501A5 (https=) | ||
| WO2023281413A1 (en) | Methods and dosing regimens comprising pf-06873600 for the treatment of cancer |